Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
WT1
MCID: WLM013
MIFTS: 66

Wilms Tumor 1 (WT1)

Categories: Blood diseases, Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Wilms Tumor 1

About this section

MalaCards integrated aliases for Wilms Tumor 1:

Name: Wilms Tumor 1 57 73 29 6
Nephroblastoma 57 12 20 43 58 36 29 6 15 71
Wilms Tumor 57 43 58 13 54 42 44 15 39
Wilms' Tumor 12 74 20 43
Wt1 57 20 73
Bilateral Wilms Tumor 20 71
Kidney, Adenomyosarcoma, Embryonal 43
Kidney, Carcinosarcoma, Embryonal 43
Nonanaplastic Kidney Wilms Tumor 71
Kidney, Embryonal Mixed Tumor 43
Childhood Kidney Wilms Tumor 71
Adult Kidney Wilms Tumor 71
Embryonal Adenosarcoma 43
Renal Embryonic Tumor 58
Wilms Tumor, Somatic 57
Adult Nephroblastoma 12
Wilms Tumor, Type 1 57
Renal Cancer, Wilms 43
Embryonal Nephroma 43
Kidney Wilms Tumor 43
Renal Adenosarcoma 43
Renal Wilms Tumor 43
Kidney, Embryoma 43
Wt1 Disorder 25
Tumor, Wilms 43
Nephroma 43

Characteristics:

Orphanet epidemiological data:

58
nephroblastoma
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United Kingdom),1-5/10000 (Europe); Age of onset: Childhood; Age of death: any age;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
genetic heterogeneity
majority of wilms tumors are sporadic
onset between 2-5 years
rare adult cases reported
5-10% of all wilms tumor are bilateral
21% of hereditary wilms tumor are bilateral
associated with several congenital malformation syndromes (wagr , abnormal urogenital development syndromes)
two-step mutation hypothesis (germline mutation followed by somatic mutation or two sequential somatic mutations)
loss of tumor suppressor gene
associated with several loci on chromosomes 11p15 (wt2, ), 16 (wt3, ), 17 (wt4, ), and 7 (wt5, ).


HPO:

31
wilms tumor 1:
Inheritance autosomal dominant inheritance somatic mutation heterogeneous


GeneReviews:

25
Penetrance The penetrance of wt1 disorder is high. it is age dependent, reaching about 90% by the end of puberty....

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases Fetal diseases
Anatomical: Nephrological diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:2154
OMIM® 57 194070
OMIM Phenotypic Series 57 PS194070
KEGG 36 H02301
MeSH 44 D009396
SNOMED-CT 67 25081006
MESH via Orphanet 45 D009396
ICD10 via Orphanet 33 C64
UMLS via Orphanet 72 C0027708
Orphanet 58 ORPHA654
MedGen 41 C0027708
UMLS 71 C0027708 C1332219 C1333015 more
Sources

Summaries for Wilms Tumor 1

About this section
GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 654DefinitionA rare malignant renal tumor, typically affecting the pediatric population, characterized by an abnormal proliferation of cells that resemble the kidney cells of an embryo (metanephroma), leading to the term embryonal tumor.EpidemiologyThe annual incidence is estimated at about 1/10,000 births and it affects boys as well as girls.Clinical descriptionNephroblastoma mainly affects young children, between the ages 1 and 5 years, but 15% of nephroblastomas occur before the age of 1 year and 2% after the age of 8 years. Adult forms are very rare. An abdominal mass (unilateral in most cases) is frequently present. Patients sometimes experience abdominal pain (around 10% of cases), hypertension, fever (20% of cases), hematuria and anemia. The evolution of the disease is very rapid, with regional dissemination in the retroperitoneal space, lymph nodes, vessels (renal vein and inferior vena cava) and in the peritoneal cavity in cases of tumor effraction, and a strong likelihood of metastases in the lungs and liver.EtiologyNephroblastoma is sporadic in 99% of cases and, among these cases, 10% are associated with congenital anomalies (aniridia, hemihypertrophy, genitourinary defects) or form part of specific syndromes (Beckwith-Wiedemann, Denys-Drash, WAGR or Perlman syndromes; see these terms). Genetic anomalies found in different chromosomal regions, including 11p13 (containing the WT1 gene), 11p15.5 (containing the H19 gene), 16q, 1p, 1q and 17p, have been found within the tumors. Familial forms are very rare (1% of cases) and are transmitted in an autosomal dominant fashion.Diagnostic methodsDiagnosis is based on imagery, particularly CT or MRI scans. The concentration of urinary metabolites of catecholamines is normal. Analysis of the extent of the disease is also conducted using imagery (ultrasound and abdominal CT analyzing particularly the liver and contralateral kidney, and thoracic radiography and CT).Differential diagnosisDifferential diagnoses include other renal tumors in children such as mesoblastic nephroma (especially in infants), clear cell sarcoma, neuroblastoma (extremely rare in the kidney but may invade the kidney by contiguity), rhabdoid tumors (see these terms) and metanephric stromal tumors.Management and treatmentDisease management is multidisciplinary and may involve chemotherapy and surgery with or without radiotherapy. Chemotherapy enables preoperative reduction in tumor size and eradicates metastases. Surgery should be accomplished without tumor effraction, which usually means that total nephrectomy is required. Nephroblastoma can be confirmed on microscopic examination, which also allows the stage of the tumor in the kidney to be evaluated. This in turn determines the choice of post-operative chemotherapy. Radiotherapy is reserved for the most extensive cases or cases with the least favorable histology.PrognosisIn the majority of cases, the prognosis is favorable with a survival rate of over 90%. Adult forms have the same prognosis and should be treated following the same methods, even when adult patients tolerate chemotherapy less well than children (which may lead to a reduction in treatment and as a result a worse prognosis).Visit the Orphanet disease page for more resources.

MalaCards based summary : Wilms Tumor 1, also known as nephroblastoma, is related to simpson-golabi-behmel syndrome and familial wilms tumor 2, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 1 is WT1 (WT1 Transcription Factor). The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include children, kidney and myeloid, and related phenotypes are abdominal pain and nephroblastoma

Disease Ontology : 12 A kidney cancer that affects the kidneys and typically located in children.

MedlinePlus Genetics : 43 Wilms tumor is a form of kidney cancer that primarily develops in children. Nearly all cases of Wilms tumor are diagnosed before the age of 10, with two-thirds being found before age 5.Wilms tumor is often first noticed because of abdominal swelling or a mass in the kidney that can be felt upon physical examination. Some affected children have abdominal pain, fever, a low number of red blood cells (anemia), blood in the urine (hematuria), or high blood pressure (hypertension). Additional signs of Wilms tumor can include loss of appetite, weight loss, nausea, vomiting, and tiredness (lethargy).Wilms tumor can develop in one or both kidneys. About 5 to 10 percent of affected individuals develop multiple tumors in one or both kidneys. Wilms tumor may spread from the kidneys to other parts of the body (metastasize). In rare cases, Wilms tumor does not involve the kidneys and occurs instead in the genital tract, bladder, abdomen, chest, or lower back. It is unclear how Wilms tumor develops in these tissues.With proper treatment, children with Wilms tumor have a 90 percent survival rate. However, the risk that the cancer will come back (recur) is between 15 and 50 percent, depending on traits of the original tumor. Tumors usually recur in the first 2 years following treatment and develop in the kidneys or other tissues, such as the lungs. Individuals who have had Wilms tumor may experience related health problems or late effects of their treatment in adulthood, such as decreased kidney function, heart disease, and development of additional cancers.

OMIM® : 57 Wilms tumor is the most common renal tumor of childhood, occurring with an incidence of 1 in 10,000 and with a median age of diagnosis between 3 and 4 years of age. Wilms tumors are thought to develop from abnormally persistent embryonal cells within nephrogenic rests. Histologically, Wilms tumor mirrors the development of the normal kidney and classically consists of 3 cell types: blastema, epithelia, and stroma (summary by Slade et al., 2010). (194070) (Updated 05-Mar-2021)

MedlinePlus : 42 Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

KEGG : 36 Nephroblastoma, also called Wilms tumor (WT), is the most common renal tumor of childhood. It can present as a single nodule, as multifocal unilateral lesions or as bilateral tumours. Typically, nephroblastoma comprises three histological components namely blastemal, epithelial and stromal. WT1, a zinc-finger transcription factor, was identified as the first nephroblastoma gene. Several other genes including CTNNB1, WTX, and TP53 have also been implicated in various stages of tumorigenesis of nephroblastoma.

UniProtKB/Swiss-Prot : 73 Wilms tumor 1: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms.

Wikipedia : 74 Wilms' tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in... more...

GeneReviews: NBK556455
Sources

Related Diseases for Wilms Tumor 1

About this section

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 987)
# Related Disease Score Top Affiliating Genes
1 simpson-golabi-behmel syndrome 32.6 GPC4 GPC3
2 familial wilms tumor 2 32.6 WT1 LOC106707172 GPC3 BRCA2
3 endometrial cancer 32.5 WT1 MEG3 IGF2 H19 BRCA2 BRAF
4 osteogenic sarcoma 32.4 WT1 MEG3 IGF2 H19 CHEK2
5 wilms tumor 5 32.4 TRIM28 POU6F2 DIS3L2 CHEK2 BRAF
6 leiomyosarcoma 32.3 WT1 IGF2 CHEK2
7 beckwith-wiedemann syndrome 32.3 WT1 MEG3 IGF2-AS IGF2 H19 GPC3
8 wilms tumor predisposition 32.2 WT1 IGF2 H19 GPC4 GPC3 DIS3L2
9 li-fraumeni syndrome 32.2 IGF2 CHEK2 BRCA2
10 pax6-related aniridia 32.1 WT1 IGF2 H19 GPC4 GPC3 BRCA2
11 serous cystadenocarcinoma 32.1 WT1 BRCA2 BRAF
12 hemihyperplasia, isolated 32.1 WT1 IGF2 H19
13 ovary adenocarcinoma 32.0 WT1 BRCA2 BRAF
14 endosalpingiosis 32.0 WT1 BRCA2 BRAF
15 ovarian gonadoblastoma 31.9 WT1 GPC3
16 wilson-turner x-linked mental retardation syndrome 31.9 WT1 POU6F2 IGF2
17 liver leiomyosarcoma 31.9 WT1 GPC3
18 metanephric adenoma 31.9 WT1 BRAF
19 seminal vesicle adenocarcinoma 31.8 WT1 GPC3
20 benign struma ovarii 31.8 WT1 BRAF
21 mayer-rokitansky-kuster-hauser syndrome 31.7 WT1 H19
22 leukemia, acute myeloid 31.7 WT1-AS WT1 MEG3 CHEK2 BRCA2
23 adenofibroma 31.4 WT1 BRAF
24 glioma 31.2 MEG3 H19 BRCA2 BRAF
25 rhabdomyosarcoma 31.2 WT1 IGF2 H19 GPC3 CHEK2 BRCA2
26 silver-russell syndrome 1 30.8 MEG3 IGF2-AS IGF2 H19
27 overgrowth syndrome 30.8 IGF2 GPC3 DIS3L2
28 renal wilms' tumor 30.7 WT1 DIS3L2
29 adrenal cortical carcinoma 30.6 IGF2 H19 BRAF
30 lynch syndrome 30.5 DIS3L2 CHEK2 BRCA2 BRAF
31 wilms tumor 2 30.4 KCNQ1DN H19
32 thyroid cancer, nonmedullary, 1 30.3 MEG3 H19 BRAF
33 choriocarcinoma 30.2 IGF2 H19 GPC3
34 global developmental delay, lung cysts, overgrowth, and wilms tumor 11.6
35 cervical wilms' tumor 11.5
36 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.4
37 wilms tumor 3 11.4
38 adult cystic nephroma 11.4
39 nephrotic syndrome, type 4 11.3
40 wilms tumor 4 11.3
41 blastema predominant kidney wilms' tumor 11.3
42 mixed cell type kidney wilms' tumor 11.3
43 adenomatoid tumor 11.2
44 metachronous kidney wilms' tumor 11.2
45 mulibrey nanism 11.2
46 mosaic variegated aneuploidy syndrome 1 11.2
47 hyperparathyroidism 2 with jaw tumors 11.2
48 mosaic variegated aneuploidy syndrome 3 11.2
49 megalencephaly-capillary malformation-polymicrogyria syndrome 11.2
50 mosaic variegated aneuploidy syndrome 11.2

Graphical network of the top 20 diseases related to Wilms Tumor 1:



Diseases related to Wilms Tumor 1
Sources

Symptoms & Phenotypes for Wilms Tumor 1

About this section

Human phenotypes related to Wilms Tumor 1:

58 31 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
2 nephroblastoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002667
3 hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0000822
4 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
5 hematuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0000790
6 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
7 neoplasm of the lung 58 31 occasional (7.5%) Occasional (29-5%) HP:0100526
8 aniridia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000526
9 neoplasm of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0002896
10 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
11 neoplasm 58 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Genitourinary Kidneys:
nephroblastoma

Neoplasia:
nephroblastoma

Clinical features from OMIM®:

194070 (Updated 05-Mar-2021)

UMLS symptoms related to Wilms Tumor 1:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.28 BRAF BRCA2 CHEK2 GPC3 IGF2 REST
Sources

Drugs & Therapeutics for Wilms Tumor 1

About this section

Drugs for Wilms Tumor 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
4
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
5
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
6
Dactinomycin Approved, Investigational Phase 4 50-76-0 2019 457193
7
Epirubicin Approved Phase 4 56420-45-2 41867
8
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 5280972 54715139
9
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
10
Pirarubicin Investigational Phase 4 72496-41-4
11 Hormones Phase 4
12 Hormone Antagonists Phase 4
13 Antifungal Agents Phase 4
14
Hydroxyitraconazole Phase 4 108222
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Immunosuppressive Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Antimitotic Agents Phase 4
20 Anti-Infective Agents Phase 4
21 Anti-Bacterial Agents Phase 4
22 Tubulin Modulators Phase 4
23 Antirheumatic Agents Phase 4
24
Liposomal doxorubicin Phase 4 31703
25
Etoposide Approved Phase 3 33419-42-0 36462
26
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
27
Sulfamethoxazole Approved Phase 3 723-46-6 5329
28
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
29
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
30
Lenograstim Approved, Investigational Phase 3 135968-09-1
31 Etoposide phosphate Phase 3
32 Calcium, Dietary Phase 3
33 Liver Extracts Phase 3
34 Cactinomycin Phase 3
35 Immunologic Factors Phase 3
36 Adjuvants, Immunologic Phase 3
37
Calcium Nutraceutical Phase 3 7440-70-2 271
38
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
39
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
40 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
41
Etanercept Approved, Investigational Phase 2 185243-69-0
42
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
43
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
45
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
46
Daunorubicin Approved Phase 2 20830-81-3 30323
47
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
49
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
50
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
2 A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma. Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
3 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
4 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
5 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Unknown status NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
6 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Unknown status NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
7 National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
8 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
9 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
10 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3
11 Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
12 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Terminated NCT01987596 Phase 3
13 Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
14 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
15 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
16 Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial Unknown status NCT00965224 Phase 2
17 Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
18 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
19 Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Completed NCT01095926 Phase 2 doxorubicin
20 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
21 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
22 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
23 Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00309907 Phase 2 methylprednisolone
24 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
25 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
26 Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2 Liposomal Vincristine
27 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
28 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
29 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
30 Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) Recruiting NCT04322318 Phase 2 Carboplatin;Cyclophosphamide;Doxorubicin;Etoposide;Ifosfamide;Irinotecan;Topotecan;Vincristine
31 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
32 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
33 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
34 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
35 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
36 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
37 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
38 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
39 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Recruiting NCT03698994 Phase 2 Ulixertinib
40 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
41 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
42 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
43 First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma Recruiting NCT02649829 Phase 1, Phase 2
44 Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial Recruiting NCT01686334 Phase 2
45 An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Active, not recruiting NCT03502785 Phase 1, Phase 2 Atezolizumab
46 An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM) Active, not recruiting NCT03491683 Phase 1, Phase 2 Temozolomide
47 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Active, not recruiting NCT02581384 Phase 1, Phase 2
48 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
49 A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
50 Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I) Not yet recruiting NCT04402073 Phase 2 Sonidegib;Cisplatin;Lomustine;Vincristine

Search NIH Clinical Center for Wilms Tumor 1

Cochrane evidence based reviews: wilms tumor

Sources

Genetic Tests for Wilms Tumor 1

About this section

Genetic tests related to Wilms Tumor 1:

# Genetic test Affiliating Genes
1 Wilms Tumor 1 29 BRCA2 GPC3 GPC4 H19 IGF2 WT1
2 Nephroblastoma 29
Sources

Anatomical Context for Wilms Tumor 1

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Wilms Tumor 1:

19
Children

MalaCards organs/tissues related to Wilms Tumor 1:

40
Kidney, Myeloid, Lung, Liver, Bone, Breast, T Cells
Sources

Publications for Wilms Tumor 1

About this section

Articles related to Wilms Tumor 1:

(show top 50) (show all 3173)
# Title Authors PMID Year
1
Vertical transmission of a mutation in exon 1 of the WT1 gene: lessons for genetic counseling. 6 57
18688870 2008
2
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 57 6
15689453 2005
3
Somatic glypican 3 (GPC3) mutations in Wilms' tumour. 57 6
12085187 2002
4
Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. 6 57
9108089 1997
5
Embryonal precursors of Wilms tumor. 61 57
31806814 2019
6
WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. 54 57
8266105 1993
7
Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. 54 57
1311084 1992
8
Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. 61 25 54
1655284 1991
9
Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. 61 57
3031816 1987
10
Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. 61 57
2995818 1985
11
Del11p13/nephroblastoma without aniridia. 61 57
6092262 1984
12
The c-Ha-ras1, insulin and beta-globin loci map outside the deletion associated with aniridia-Wilms' tumour. 57 61
6312329 1983
13
Glomerulonephritis associated with male pseudohermaphroditism and nephroblastoma. 61 57
6307071 1983
14
Familial occurrence of Wilms' tumor: nephroblastoma in one of monozygous twins and in another sibling. 57 61
164771 1975
15
Pineal teratoma with nephroblastic component in a newborn male: Case report and review of the literature. 61 42
33099347 2020
16
Mutations in the transcriptional repressor REST predispose to Wilms tumor. 6
26551668 2015
17
Towards an understanding of kidney diseases associated with WT1 mutations. 61 25
26154924 2015
18
Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. 57
25190313 2014
19
Discordant expression of a new WT1 gene mutation in a family with monozygotic twins presenting with congenital nephrotic syndrome. 25 61
21614510 2012
20
Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. 57
19948536 2010
21
Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. 57
20106868 2010
22
Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. 6
18836444 2008
23
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. 57
17204608 2007
24
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
25
Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. 6
15459955 2004
26
Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. 57
15254018 2004
27
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
28
Chromosome 1q expression profiling and relapse in Wilms' tumour. 57
12241781 2002
29
Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours. 6
11284034 2001
30
Absence of PPP2R1A mutations in Wilms tumor. 57
11360189 2001
31
Wilms' tumor and related abnormalities in the fetus and newborn. 57
10475544 1999
32
A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. 57
10077614 1999
33
Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. 57
9781906 1998
34
Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. 57
9537236 1998
35
Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour. 57
9425891 1998
36
A clinical overview of WT1 gene mutations. 6
9090524 1997
37
Familial Wilms' tumor associated with a WT1 zinc finger mutation. 6
8975729 1996
38
Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. 57
8696342 1996
39
[Hereditary renal tumors: Wilms' tumor--congenital anomalies' syndrome]. 57
8538037 1995
40
Absence of mutations in the WT1 gene in patients with XY gonadal dysgenesis. 57
7607640 1995
41
DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. 6
7795587 1995
42
Fine structure analysis of the WT1 gene in sporadic Wilms tumors. 57
8170946 1994
43
Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. 57
8298644 1993
44
Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor. 57
8402654 1993
45
Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. 6
8388765 1993
46
A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. 57
1321431 1992
47
WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. 6
1654525 1991
48
Familial predisposition to Wilms tumor does not segregate with the WT1 gene. 57
1655633 1991
49
Constitutional extra chromosomal element in a family with Wilms' tumor. 57
1648545 1991
50
Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. 57
1646159 1991
Sources

Variations for Wilms Tumor 1

About this section

ClinVar genetic disease variations for Wilms Tumor 1:

6 (show top 50) (show all 943)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TET2-AS1 NM_001127208.2(TET2):c.4456T>C (p.Ser1486Pro) SNV other 438791 rs1553918194 4:106193994-106193994 4:105272837-105272837
2 MED12 NM_005120.3(MED12):c.131G>A (p.Gly44Asp) SNV other 92220 rs199469672 X:70339254-70339254 X:71119404-71119404
3 FZD6 NM_003506.4(FZD6):c.346C>T (p.Arg116Ter) SNV other 438765 rs769116796 8:104330986-104330986 8:103318758-103318758
4 CTNNB1 NM_001904.4(CTNNB1):c.770C>T (p.Thr257Ile) SNV other 438758 rs1553630452 3:41267186-41267186 3:41225695-41225695
5 CTNNB1 NM_001904.4(CTNNB1):c.133_135del (p.Ser45del) Deletion other 17576 rs587776850 3:41266136-41266138 3:41224643-41224645
6 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV other 17588 rs121913409 3:41266137-41266137 3:41224646-41224646
7 CHEK2 NM_007194.4(CHEK2):c.1100_1101del (p.Thr367fs) Deletion Pathogenic 438773 rs1555913934 22:29091856-29091857 22:28695868-28695869
8 WT1 NM_024426.6(WT1):c.880_882del (p.Tyr294del) Deletion Pathogenic 438757 rs1554945033 11:32449507-32449509 11:32427961-32427963
9 WT1 NC_000011.10:g.(?_32396251)_(32417660_?)del Deletion Pathogenic 476672 11:32417797-32439206 11:32396251-32417660
10 WT1 NM_024426.6(WT1):c.812del (p.Pro271fs) Deletion Pathogenic 406680 rs1060501253 11:32449577-32449577 11:32428031-32428031
11 WT1 NM_024426.6(WT1):c.1387C>T (p.Arg463Ter) SNV Pathogenic 3494 rs121907909 11:32413578-32413578 11:32392032-32392032
12 WT1 NM_024426.6(WT1):c.592del (p.Ala198fs) Deletion Pathogenic 429033 rs1131690795 11:32456315-32456315 11:32434769-32434769
13 WT1 NM_024426.6(WT1):c.682dup (p.Asp228fs) Duplication Pathogenic 476713 rs1554945232 11:32450144-32450145 11:32428598-32428599
14 WT1 NM_024426.6(WT1):c.334del (p.Asp112fs) Deletion Pathogenic 476700 rs1554946600 11:32456573-32456573 11:32435027-32435027
15 GPC3 NM_001164617.2(GPC3):c.1228C>T (p.Arg410Ter) SNV Pathogenic 11694 rs122453121 X:132833930-132833930 X:133699902-133699902
16 WT1 NM_024426.6(WT1):c.1120C>T (p.Arg374Ter) SNV Pathogenic 449416 rs1423753702 11:32417947-32417947 11:32396401-32396401
17 WT1 NM_024426.6(WT1):c.1149del (p.Val384fs) Deletion Pathogenic 543120 rs1554939839 11:32417918-32417918 11:32396372-32396372
18 GPC3 NM_004484.3(GPC3):c.595C>T (p.Arg199Ter) SNV Pathogenic 11689 rs104894855 X:132887946-132887946 X:133753919-133753919
19 WT1 NM_024426.6(WT1):c.653del (p.Arg218fs) Deletion Pathogenic 571628 rs1565000973 11:32456254-32456254 11:32434708-32434708
20 WT1 NM_024426.6(WT1):c.478C>T (p.Gln160Ter) SNV Pathogenic 543125 rs1554946500 11:32456429-32456429 11:32434883-32434883
21 WT1 NM_024426.6(WT1):c.1303C>T (p.Arg435Ter) SNV Pathogenic 3497 rs121907906 11:32414263-32414263 11:32392717-32392717
22 WT1 NM_024426.6(WT1):c.1120C>T (p.Arg374Ter) SNV Pathogenic 449416 rs1423753702 11:32417947-32417947 11:32396401-32396401
23 WT1 NM_024426.6(WT1):c.472G>T (p.Glu158Ter) SNV Pathogenic 584762 rs1565001383 11:32456435-32456435 11:32434889-32434889
24 WT1 NM_024426.6(WT1):c.1303C>T (p.Arg435Ter) SNV Pathogenic 3497 rs121907906 11:32414263-32414263 11:32392717-32392717
25 LOC106707172 NC_000011.10:g.(?_32389048)_(32435355_?)del Deletion Pathogenic 665054 11:32410594-32456901 11:32389048-32435355
26 GPC3 NM_004484.4(GPC3):c.256C>T (p.Arg86Ter) SNV Pathogenic 935437 X:133087158-133087158 X:133953131-133953131
27 TRIM28 NM_005762.3(TRIM28):c.2101C>T (p.Gln701Ter) SNV Pathogenic 973190 19:59061222-59061222 19:58549855-58549855
28 POU6F2 NM_007252.4(POU6F2):c.573G>T (p.Gln191His) SNV Pathogenic 1871 rs121918261 7:39379302-39379302 7:39339703-39339703
29 POU6F2 POU6F2, C-G, EXON 1C, 5-PRIME UTR SNV Pathogenic 1872
30 WT1 NM_024426.6(WT1):c.893_909del (p.Asn298fs) Deletion Pathogenic 3484 rs587776573 11:32439179-32439195 11:32417633-32417649
31 WT1 NM_024426.6(WT1):c.1094del (p.Gly365fs) Deletion Pathogenic 3485 rs587776574 11:32421513-32421513 11:32399967-32399967
32 WT1 NM_024426.6(WT1):c.1387C>T (p.Arg463Ter) SNV Pathogenic 3494 rs121907909 11:32413578-32413578 11:32392032-32392032
33 WT1 NM_024426.6(WT1):c.1303C>T (p.Arg435Ter) SNV Pathogenic 3497 rs121907906 11:32414263-32414263 11:32392717-32392717
34 WT1 NM_024426.6(WT1):c.546C>A (p.Tyr182Ter) SNV Pathogenic 3506 rs121907911 11:32456361-32456361 11:32434815-32434815
35 H19 H19, 5.3-KB DEL Deletion Pathogenic 18243
36 H19 H19, 1.43-KB TRIPLICATION Variation Pathogenic 18244
37 H19 NR_002196.1(H19):n.-7080_-1781del Deletion Pathogenic 162493 11:1999616-2004919
38 H19 GRCh38/hg38 11p15.5(chr11:2000799-2001783)x3 copy number gain Pathogenic 162494 11:2022018-2023452 11:2000788-2002222
39 GPC3 NM_004484.4(GPC3):c.271C>T (p.Gln91Ter) SNV Pathogenic 941300 X:133087143-133087143 X:133953116-133953116
40 GPC3 NM_004484.4(GPC3):c.1269G>A (p.Trp423Ter) SNV Pathogenic 941417 X:132826420-132826420 X:133692392-133692392
41 GPC3 NM_004484.3(GPC3):c.1471G>T (p.Glu491Ter) SNV Pathogenic 565351 rs1569392947 X:132730570-132730570 X:133596542-133596542
42 GPC3 NM_004484.3(GPC3):c.1307del (p.Ala436fs) Deletion Pathogenic 575598 rs1569408743 X:132795864-132795864 X:133661836-133661836
43 GPC3 NC_000023.10:g.(?_132795738)_(133119496_?)del Deletion Pathogenic 583690 X:132795738-133119496
44 GPC3 NM_001164617.2(GPC3):c.629_654delinsCTTGCA (p.Asn210fs) Indel Pathogenic 476661 rs1556297749 X:132887887-132887912 X:133753860-133753885
45 GPC3 NM_004484.4(GPC3):c.80dup (p.Pro28fs) Duplication Pathogenic 656012 rs1602581162 X:133119396-133119397 X:133985369-133985370
46 GPC3 NM_004484.4(GPC3):c.513dup (p.Asp172Ter) Duplication Pathogenic 664988 rs1603240717 X:132888027-132888028 X:133754000-133754001
47 GPC3 NM_004484.4(GPC3):c.460_463dup (p.Tyr155fs) Microsatellite Pathogenic 940806 X:132888077-132888078 X:133754050-133754051
48 GPC3 NM_004484.3(GPC3):c.1574-?_*379+?del Deletion Pathogenic 239938
49 GPC3 NC_000023.10:g.(?_132795758)_(132888203_?)del Deletion Pathogenic 417449 X:132795758-132888203
50 GPC3 NM_004484.3(GPC3):c.361C>T (p.His121Tyr) SNV Pathogenic 11690 rs122453119 X:132888180-132888180 X:133754153-133754153

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 1:

73
# Symbol AA change Variation ID SNP ID
1 WT1 p.Pro181Ser VAR_007739 rs2234584
2 WT1 p.Ser223Asn VAR_007740
3 WT1 p.Gly253Ala VAR_007741
4 WT1 p.Arg366Cys VAR_007745
5 WT1 p.Arg366His VAR_007746
6 WT1 p.His373Gln VAR_007747
7 WT1 p.Arg394Trp VAR_007750
8 WT1 p.Cys355Gly VAR_043799
9 WT1 p.Arg394Leu VAR_043807

Copy number variations for Wilms Tumor 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 24429 1 180300000 185800000 Microamplification CACNA1E Nephroblastoma
Sources

Expression for Wilms Tumor 1

About this section
Search GEO for disease gene expression data for Wilms Tumor 1.
Sources

Pathways for Wilms Tumor 1

About this section
Sources

GO Terms for Wilms Tumor 1

About this section

Biological processes related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.91 WT1 TRIP13 REST POU6F2 IGF2 CHEK2
2 cellular response to drug GO:0035690 9.43 REST CHEK2 BRAF
3 oocyte maturation GO:0001556 9.4 TRIP13 BRCA2
4 double-strand break repair GO:0006302 9.33 TRIP13 CHEK2 BRCA2
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 CHEK2 BRCA2
6 regulation of protein localization to membrane GO:1905475 8.96 GPC4 GPC3
7 embryonic placenta morphogenesis GO:0060669 8.62 TRIM28 IGF2
Sources

Sources for Wilms Tumor 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....